Brain-computer interface technology is poised to enter a significant phase of commercial expansion, with 2026 expected to mark the beginning of its large-scale application, according to Jin10. The A-share market currently has fewer than 30 stocks related to the brain-computer interface concept. Some of these stocks are indirectly involved through investments in brain-computer interface companies, while others are developing the technology in collaboration with academic institutions or through independent research.
Institutional research has highlighted the progress of these concept stocks. According to Databao, as of the close on April 3, five concept stocks have been surveyed by over 100 institutions this year. These stocks include Xiangyu Medical, Aipeng Medical, Entropy Technology, Botuo Biological, and 37 Interactive Entertainment.